BioTime Inc. (NYSE:BTX) said today that its subsidiary, Cell Cure Neurosciences, has landed a $2 million grant from the Israel Innovation Authority for the development of its dry-AMD therapy, OpRegen.
The Alameda, Calif.-based company’s OpRegen is an investigational therapy that delivers retinal pigment epithelial cells into the subretinal space to replace lost RPE cells.
Get the full story at our sister site, Drug Delivery Business News.
The post BioTime lands $2m for dry-AMD therapy appeared first on MassDevice.
from MassDevice http://ift.tt/2wXJx4s
Cap comentari:
Publica un comentari a l'entrada